| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.28865 |
| P698 | PubMed publication ID | 24668305 |
| P50 | author | Steven A Belinsky | Q96685352 |
| P2093 | author name string | Pietro Taverna | |
| Thomas H March | |||
| Matthew D Reed | |||
| Aram Oganesian | |||
| Yushi Liu | |||
| Carmen S Tellez | |||
| Marcie J Grimes | |||
| Maria A Picchi | |||
| P2860 | cites work | Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma | Q46455509 |
| DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci | Q22254582 | ||
| The Polycomb group protein EZH2 directly controls DNA methylation | Q24299020 | ||
| Histone acetylation in chromatin structure and transcription | Q28131749 | ||
| DNA methyltransferase Dnmt1 associates with histone deacetylase activity | Q28141500 | ||
| Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells | Q28142463 | ||
| Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin | Q28187783 | ||
| Histone acetylation and transcriptional regulatory mechanisms | Q29547707 | ||
| The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura | Q33259359 | ||
| HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells | Q33344484 | ||
| Apoptotic and autophagic cell death induced by histone deacetylase inhibitors | Q33583208 | ||
| A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas | Q33619776 | ||
| Role of covalent modifications of histones in regulating gene expression | Q33775005 | ||
| S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth | Q33843593 | ||
| Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors | Q33926864 | ||
| A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer | Q34126908 | ||
| Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin | Q34188997 | ||
| Dynamics of histone acetylation in vivo. A function for acetylation turnover? | Q34746928 | ||
| 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy | Q34770609 | ||
| Reactivating the expression of methylation silenced genes in human cancer | Q34770617 | ||
| HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL | Q35553330 | ||
| Preclinical Studies on Histone Deacetylase Inhibitors as Therapeutic Reagents for Endometrial and Ovarian Cancers | Q35739684 | ||
| Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine | Q35750354 | ||
| Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer | Q35964716 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| Epigenetic resensitization to platinum in ovarian cancer | Q36979382 | ||
| High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. | Q37031262 | ||
| Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model | Q37214386 | ||
| Targeting DNA methylation | Q37320354 | ||
| Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine | Q37576837 | ||
| Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. | Q39247530 | ||
| 5-azacytidine treatment reorganizes genomic histone modification patterns | Q39289082 | ||
| Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model | Q39609163 | ||
| Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models | Q39970361 | ||
| Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides | Q40110178 | ||
| Refinement of an orthotopic lung cancer model in the nude rat. | Q40778547 | ||
| Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells | Q40788118 | ||
| Cellular differentiation, cytidine analogs and DNA methylation | Q42242732 | ||
| Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells | Q44257942 | ||
| The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine | Q44737509 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | entinostat | Q1281020 |
| P304 | page(s) | 2223-2231 | |
| P577 | publication date | 2014-04-05 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome | |
| P478 | volume | 135 |
| Q35048054 | Augmenting antitumor immune responses with epigenetic modifying agents |
| Q38614582 | CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer |
| Q33798842 | Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study |
| Q36020996 | Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells |
| Q37391981 | Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. |
| Q38534163 | Entinostat (SNDX-275) for the treatment of non-small cell lung cancer |
| Q60044740 | Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors |
| Q38459836 | Epigenetic therapy for solid tumors: from bench science to clinical trials |
| Q38854734 | Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin |
| Q88723991 | Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma |
| Q34547269 | Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs |
| Q36213724 | TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells |
| Q47417938 | The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. |
| Q35870933 | The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells |
| Q53810338 | Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy? |
Search more.